Cambridge Investment Research Advisors’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NRXPW Stock Details NRXPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-10,000	Closed	-$9K	–	3164
2022 Q1	$9K	Sell	10,000 -19,450	-66%	-$28.7K	﹤0.01%	3144
2021 Q4	$54K	Buy	29,450 +12,480	+74%	+$39.5K	﹤0.01%	3098
2021 Q3	$81K	Buy	+16,970	New	+$105K	﹤0.01%	2982

Other funds holding NRXPW

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.95% 1-Year Est. Return

Cambridge Investment Research Advisors's NRXPW Position: Q2 2022 in Review

Cambridge Investment Research Advisors sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q2 2022, closing a stake of 10,000 shares — an estimated $9K sold.

Cambridge Investment Research Advisors first reported a position in NRXPW in Q3 2021 and held it in 3 quarters. The position peaked at $81K in Q3 2021. 4 funds tracked by Wall St. Rank hold NRXPW as of Q2 2022.

Cambridge Investment Research Advisors reported no remaining NRX Pharmaceuticals Warrant position as of Q2 2022 after selling out during the quarter.
Cambridge Investment Research Advisors sold 10,000 NRX Pharmaceuticals Warrant shares in Q2 2022, an estimated $9K.
Cambridge Investment Research Advisors first reported a position in NRX Pharmaceuticals Warrant in Q3 2021 and held it in 3 quarters.
Cambridge Investment Research Advisors's NRX Pharmaceuticals Warrant position peaked at $81K in Q3 2021.
4 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q2 2022.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2022, filed 13 Jul 2022.